OncRef

Clinical Trial: NCT05298423

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Merck Sharp & Dohme LLC
Information Provided By:Merck Sharp & Dohme LLC
Last Update Posted:2026-08-28

Study Overview

Brief Summary

Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab.

Official Title

Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC

Conditions

Carcinoma, Non-Small-Cell Lung

Intervention / Treatment

  • Biological: pembrolizumab/vibostolimab
  • Biological: durvalumab
  • Drug: cisplatin
  • Drug: pemetrexed
  • Drug: etoposide
  • Drug: carboplatin
  • Drug: paclitaxel
  • Radiation: thoracic radiotherapy

Other Study ID Numbers

  • 7684A-006
  • MK-7684A-006
  • KEYVIBE-006
  • jRCT2021220015
  • PHRR230831-006071
  • 2022-502752-31-00
  • U1111-1285-3656
  • 2021-005135-23

Start Date (Actual)

2022-05-03

Primary Completion Date (Actual)

2026-06-15

Study Completion Date (Actual)

2026-06-15

Enrollment (Actual)

610

Study Type

Interventional

Phase

Phase 3